GlassScriptPhysician profile
Luis Maldonado
NPI 1619908639
$10,653.06
in general payments reported to CMS, 2019-2025
18 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $850 · 2021: $1,897 · 2022: $1,476 · 2023: $2,149 · 2024: $1,961 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,172.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,585.91 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,678.20 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,186.36 | 2019-2024 | Trintellix |
| Acadia Pharmaceuticals INC | $1,071.16 | 2019-2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $719.48 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $593.28 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $575.88 | 2019-2021 | |
| Lundbeck LLC | $420.30 | 2020-2024 | Rexulti |
| Axsome Therapeutics, INC. | $411.41 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $342.71 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.33 | 2021-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $241.41 | 2020-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $224.74 | 2022-2023 | Austedo, Uzedy |
| Allergan, INC. | $207.64 | 2019 | |
| Shire North American Group INC | $53.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $42.58 | 2024 | Azstarys |
| Cmp Pharma, INC. | $35.54 | 2022 | |
| Merck Sharp & Dohme LLC | $17.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Maldonado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.